Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer Eligible patients had stage IIB to IIIB ...
In the article that accompanies this editorial, Rahman et al 2 describe the results from the first three experimental arms of the INSIGhT trial which, to our knowledge, is the first adaptive platform ...
Pharmaceutical companies will accelerate adoption of adaptive clinical trial designs, according to the Tufts Center for Drug Development, to reduce clinical development timelines and costs while ...
BOSTON, April 25, 2011 /PRNewswire/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced ...
Response-adaptive designs allow the randomization probabilities to change during the course of a trial based on cumulated response data so that a greater proportion of patients can be allocated to the ...
Pharmaceutical companies will accelerate adoption of adaptive clinical trial designs, according to the Tufts Center for Drug Development, to reduce clinical development timelines and costs while ...
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized ...
A breast cancer screening study that pairs oncology therapies with biological markers (biomarkers) launched by a consortium of public health agencies, academics and companies is being heralded as a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback